Lombard Odier Asset Management Europe Ltd Decreases Stock Position in Stryker Corporation $SYK

Lombard Odier Asset Management Europe Ltd decreased its position in Stryker Corporation (NYSE:SYK) by 18.2% during the 1st quarter, Holdings Channel reports. The fund owned 8,175 shares of the medical technology company’s stock after selling 1,825 shares during the quarter. Lombard Odier Asset Management Europe Ltd’s holdings in Stryker were worth $2,686,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Sankala Group LLC acquired a new position in Stryker in the fourth quarter valued at approximately $26,000. Godfrey Financial Associates Inc. acquired a new position in shares of Stryker in the 4th quarter valued at $26,000. United Financial Planning Group LLC acquired a new position in Stryker in the third quarter valued at $27,000. Atlas Capital Advisors Inc. purchased a new position in shares of Stryker in the 4th quarter valued at approximately $27,000. Finally, DJE Kapital AG acquired a new stake in shares of Stryker during the fourth quarter worth $28,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Stryker

In related news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 in the last three months. Corporate insiders own 4.60% of the company’s stock.

Stryker Stock Performance

Stryker stock opened at $326.41 on Monday. The company has a market cap of $125.13 billion, a price-to-earnings ratio of 33.82, a price-to-earnings-growth ratio of 2.08 and a beta of 0.76. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $401.99. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The stock’s 50-day moving average is $317.28 and its 200-day moving average is $334.73.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same period in the prior year, the company earned $3.13 EPS. The firm’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts anticipate that Stryker Corporation will post 15.01 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th were issued a dividend of $0.88 per share. The ex-dividend date was Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is currently 36.48%.

Analysts Set New Price Targets

A number of brokerages have weighed in on SYK. Piper Sandler lowered their price objective on Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a report on Friday. Barclays lowered their price objective on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research note on Monday, May 4th. Weiss Ratings downgraded Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Evercore set a $350.00 price objective on shares of Stryker in a research report on Monday, July 6th. Finally, UBS Group initiated coverage on Stryker in a report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average price target of $387.88.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reported second-quarter revenue of $6.59 billion, up 9.4% year over year, while adjusted EPS of $3.69 exceeded consensus estimates. Organic sales growth reached 9%, supported by strong demand for orthopedic, spinal and other medical devices. Stryker beats quarterly estimates on strong demand for medical devices
• Positive Sentiment: Management said it has regained momentum following the cyber disruption and resumed share repurchases. Its full-year guidance calls for 8.3% to 9.3% organic sales growth and adjusted EPS of $14.95 to $15.10. Stryker expects 2026 organic sales growth and adjusted EPS
• Positive Sentiment: JPMorgan maintained an “overweight” rating, although it reduced its price target to $350. Truist raised its target to $340 while retaining a “hold” rating, and BTIG continues to rate the shares “buy.”
• Neutral Sentiment: The updated guidance was narrower but remained broadly close to prior expectations and analyst forecasts. This suggests operational stability, but not a major upside revision that could drive a stronger investor reaction.
• Neutral Sentiment: Analyst opinion remains generally constructive, with no recent sell ratings cited and a six-month median price target of $385, though target reductions indicate some caution regarding valuation or near-term upside.
• Negative Sentiment: The main pressure on SYK appears to be an expectations reset: despite the earnings beat, investors had anticipated a more substantial increase to full-year guidance after the cyberattack recovery. SYK falls despite Q2 earnings beat
• Negative Sentiment: Reported insider activity has been heavily weighted toward selling, with no purchases and substantial sales over the past six months. This may add to investor concerns about valuation and management confidence, although the trades do not necessarily reflect current operating performance.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.